2026 Kathleen M. Sakamoto: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	52	16508	15156	6835	6108	248	13235

Overview

Kathleen M. Sakamoto is affiliated with Stanford University in the United States. Their research spans several domains within medicine and biochemistry, genetics, and molecular biology, with a strong focus on hematology and cancer-related studies.

Their recent publications demonstrate engagement with cutting-edge topics in oncology and hematology, including:

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity (2021, Cancer Cell)
Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic (2020, Pediatric Blood & Cancer)
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia (2021, Blood)
Metabolomics in acute myeloid leukemia (2020, Molecular Genetics and Metabolism)
RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit (2020, Oncotarget)

Kathleen M. Sakamoto has frequent co-authorship collaborations with:

Norman J. Lacayo (23 co-authored papers)
Mark C. Wilkes (17 co-authored papers)
Hee-Don Chae (12 co-authored papers)
Nobuko Hijiya (10 co-authored papers)
Anupama Narla (10 co-authored papers)

The scientist commonly publishes in the following venues:

Blood (22 publications)
Cancer Research (5 publications)
Cancers (4 publications)
Experimental Hematology (4 publications)
Nature Communications (3 publications)

Main fields of study covered by Kathleen M. Sakamoto include:

Medicine (99 publications)
Biochemistry, Genetics and Molecular Biology (81 publications)

Their subfields of study focus largely on:

Molecular Biology (66 publications)
Hematology (36 publications)
Genetics (17 publications)
Public Health, Environmental and Occupational Health (14 publications)
Epidemiology (8 publications)

The primary research topics evident from their work encompass:

RNA modifications and cancer (40 publications)
Acute Myeloid Leukemia Research (38 publications)
Acute Lymphoblastic Leukemia research (26 publications)
Chronic Myeloid Leukemia Treatments (26 publications)
Cancer-related gene regulation (22 publications)
Chronic Lymphocytic Leukemia Research (14 publications)
Epigenetics and DNA Methylation (14 publications)

Best Publications

Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.

Kathleen M. Sakamoto;Kyung B. Kim;Akiko Kumagai;Frank Mercurio

1950
Citations
The role of the transcription factor CREB in immune function.

Andy Y. Wen;Kathleen M. Sakamoto;Lloyd S. Miller

977
Citations
The Role of HDAC6 in Cancer

Grace I. Aldana-Masangkay;Kathleen M. Sakamoto

484
Citations
Chemical genetic control of protein levels: selective in vivo targeted degradation.

John S. Schneekloth;Fabiana N. Fonseca;Michael Koldobskiy;Amit Mandal

480
Citations
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia

Charlotte M. Niemeyer;Michelle W. Kang;Danielle H. Shin;Ingrid Furlan

406
Citations
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation

Kathleen M. Sakamoto;Kathleen M. Sakamoto;Kyung B. Kim;Rati Verma;Andy Ransick

395
Citations
Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family.

Nadia Danilova;Kathleen M. Sakamoto;Kathleen M. Sakamoto;Shuo Lin

385
Citations
CREB in the Pathophysiology of Cancer: Implications for Targeting Transcription Factors for Cancer Therapy

Kathleen M. Sakamoto;David A. Frank

354
Citations
The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia

Deepa B. Shankar;Jerry C. Cheng;Kentaro Kinjo;Noah Federman

320
Citations
Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation.

Agustin Rodriguez-Gonzalez;Tara Lin;Alan K. Ikeda;Tiffany R Simms-Waldrip

248
Citations
Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain

Rati Verma;Noel R. Peters;Mariapina D'Onofrio;Gregory P. Tochtrop

239
Citations
BUBR1 deficiency results in abnormal megakaryopoiesis

Qi Wang;Tongyi Liu;Yuqiang Fang;Suqing Xie

220
Citations
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.

A Rodriguez-Gonzalez;K Cyrus;M Salcius;K Kim

213
Citations
Targeting CREB for cancer therapy: friend or foe.

Xiangshu Xiao;Bingbing X Li;Bryan Mitton;Alan Ikeda

193
Citations
Stress-induced stimulation of early growth response gene-1 by p38/stress-activated protein kinase 2 is mediated by a cAMP-responsive promoter element in a MAPKAP kinase 2-independent manner.

Malvyne Rolli;Alexey Kotlyarov;Kathleen M. Sakamoto;Matthias Gaestel

178
Citations
Net1 stimulates RNA polymerase I transcription and regulates nucleolar structure independently of controlling mitotic exit.

Wenying Shou;Kathleen M Sakamoto;Kathleen M Sakamoto;John Keener;Kenji W Morimoto

171
Citations
FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.

Bertrand W. Parcells;Alan K. Ikeda;Tiffany Simms-Waldrip;Theodore B. Moore

142
Citations
Granulocyte-macrophage colony-stimulating factor and interleukin-3 signaling pathways converge on the CREB-binding site in the human egr-1 promoter.

K. M. Sakamoto;J. K. Fraser;Hu-Jung J. Lee;E. Lehman

134
Citations
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

Deepa B. Shankar;Junling Li;Paul Tapang;J. Owen McCall

121
Citations
RNA interference and human disease.

Jerry C Cheng;Theodore B Moore;Kathleen M Sakamoto

119
Citations